TG Therapeutics (NASDAQ:TGTX) Stock Rating Upgraded by StockNews.com

TG Therapeutics (NASDAQ:TGTX - Get Free Report) was upgraded by stock analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

A number of other analysts have also issued reports on the stock. TD Cowen assumed coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They set a "buy" rating and a $50.00 price target on the stock. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research note on Monday, November 25th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. Finally, HC Wainwright upped their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Trading Up 4.3 %

Shares of NASDAQ:TGTX traded up $1.33 during mid-day trading on Friday, reaching $32.02. 2,117,001 shares of the company were exchanged, compared to its average volume of 3,604,403. TG Therapeutics has a 1 year low of $12.84 and a 1 year high of $36.84. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm's 50-day simple moving average is $28.56 and its 200 day simple moving average is $23.40. The firm has a market cap of $4.98 billion, a price-to-earnings ratio of -320.17 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to analysts' expectations of $81.68 million. During the same quarter in the prior year, the business earned $0.73 earnings per share. The company's quarterly revenue was down 49.4% on a year-over-year basis. Equities research analysts forecast that TG Therapeutics will post 0.17 EPS for the current year.

Insider Activity at TG Therapeutics

In other news, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the transaction, the director now owns 100,195 shares in the company, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp lifted its position in shares of TG Therapeutics by 35.8% during the 3rd quarter. State Street Corp now owns 9,094,158 shares of the biopharmaceutical company's stock worth $212,712,000 after buying an additional 2,398,015 shares during the last quarter. Marshall Wace LLP acquired a new position in TG Therapeutics in the second quarter valued at $36,501,000. Hood River Capital Management LLC boosted its stake in TG Therapeutics by 6.7% in the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company's stock valued at $27,982,000 after acquiring an additional 98,892 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of TG Therapeutics by 0.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,184,609 shares of the biopharmaceutical company's stock worth $27,708,000 after purchasing an additional 7,939 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of TG Therapeutics by 1,549.4% in the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company's stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.